Laboratory Quality Controls for Stem Cell Therapy in Cancún, México | Regeneris
Quality System Deep Dive
Laboratory Quality Controls Behind a Stem Cell Dose — in Cancún, México
Every mesenchymal stem cell (MSC) dose released at Regeneris in Cancún, México passes a documented chain of controls — cleanroom classification, environmental monitoring, sterility and mycoplasma testing, identity and potency characterization, and a formal lot-release sign-off. This page walks through that quality system in plain language so you can ask the right questions of any clinic, anywhere.
Classified, monitored space for sterile processing
Sterility
Per-lot microbiology and mycoplasma testing
ISCT
Identity, viability, purity vs. minimal criteria
TL;DR — what really happens before a dose is released
In Cancún, México, our partner laboratory operates under a documented quality system: cells are expanded in a classified cleanroom with continuous environmental monitoring; each lot is tested for sterility and mycoplasma; identity, viability, and purity are characterized against ISCT criteria; and a designated quality unit signs the lot release before any dose leaves the lab. Nothing is shipped without a release record — and your clinical team in Cancún reviews the certificate of analysis with you on consult day.
Quick facts — at a glance
Clinic name
Regeneris Therapy
Location
Cancún, Quintana Roo, México
Cleanroom model
Classified, monitored environment under a documented quality system
Reported per lot; lots below the validated threshold are rejected
Potency
Defined assay or assay matrix linking the lot to intended biological function
Lot release
Quality-unit sign-off independent of production; CoA accompanies every dose
Regulator
Plain-language overview
What 'laboratory quality controls' actually means
When a clinic in Cancún, México tells you the cells you will receive are 'lab-grade' or 'GMP-compliant', that claim only carries weight if it sits on top of a documented quality system. A quality system is not a single test — it is the whole chain of rules, records, and people that decide whether a batch of cells is allowed to leave the lab. Below are the four pillars patients should expect to see, each of which is described in the rest of this page.
1 — Classified cleanroom & environment
Cell expansion happens inside a classified cleanroom — a sealed space whose airborne particle counts and microbial load are controlled to defined limits.
Operators use cascade gowning, validated air-handling units with HEPA filtration, and unidirectional airflow over the critical work zone.
Cleanroom & environment
What a 'classified cleanroom' actually is
Classification is the language regulators use to talk about how clean the air is. In the European GMP framework — widely referenced for advanced therapies — sterile manufacturing happens inside graded spaces (Grade A, B, C, D) defined by airborne particle limits and microbial monitoring limits, both 'at rest' and 'in operation'. Grade A is the cleanest zone — typically the unidirectional-airflow workspace where open cell manipulation occurs — with Grade B as its surrounding background room. ISO 14644-1 provides the underlying particle-cleanliness numbers (e.g., ISO Class 5).
Particle control
Microbiological safety
Sterility, mycoplasma, and endotoxin — three different questions
Patients often hear 'sterile' as one word, but the laboratory asks three questions, each with its own test. The three answers together — none on its own — are what makes a stem cell lot defensibly safe to infuse.
Sterility — is the lot free of bacteria and fungi?
Sterility testing in cellular therapy is governed in the United States by 21 CFR 610.12, which defines the framework for testing biological products for the presence of viable contaminating microorganisms. Compendial methods (USP 〈71〉 and equivalent) culture an aliquot in media that support a broad range of bacteria and fungi; the test takes days, which is why parallel rapid microbiological methods are often used to inform early decisions. In Cancún, México, sterility data appears on the release certificate that your physician walks through with you.
Mycoplasma — is the culture invisibly colonized?
Mycoplasmas are fastidious bacteria without a cell wall; they pass through standard 0.2 µm filters and can colonize cell cultures without changing color or turbidity. Detecting them requires a dedicated test (culture, indicator-cell DNA staining, or nucleic-acid amplification). It is a release-criterion separate from sterility because a mycoplasma-positive culture can look healthy by routine microbiology and still alter cell behavior.
Endotoxin — how much bacterial cell-wall fragment is present?
Identity, viability & purity
Characterizing the cells against the ISCT criteria
The International Society for Cellular Therapy (ISCT) published a position statement in 2006 defining three minimum criteria to call a population a multipotent mesenchymal stromal cell. Those criteria remain the global reference for MSC identity and are how a serious laboratory tells patients — and regulators — what is actually in the vial.
1 — Adherence and morphology
The cells must adhere to standard tissue-culture plastic under defined conditions, with the elongated fibroblast-like morphology characteristic of MSCs documented as the culture expands.
2 — Surface-marker fingerprint by flow cytometry
≥95% of the cells must express CD73, CD90, and CD105, while ≤2% express the hematopoietic and endothelial lineage markers CD45, CD34, CD14 or CD11b, CD79α or CD19, and HLA-DR. This phenotype is verified by flow cytometry as part of lot release.
Beyond identity
Potency — testing function, not just identity
Identity tells you what the cells are; potency tells you what they can do. The ISCT and the broader field have moved toward an 'assay matrix' approach because MSC therapeutic effect is multifactorial — immunomodulatory, paracrine, and regenerative pathways rarely reduce to a single number. A combination of bioassays and analytical methods is favored to define MSC potency more adequately than any single test could.
Why a matrix, not a single test
A single in vitro assay rarely captures the full clinical mechanism. Combining functional readouts (for example, T-cell suppression and cytokine response) with secretome or transcriptome markers gives a more defensible picture of what a lot can do.
Definitions you can quote
Quality-system terms in one sentence each
Short, citation-ready definitions of the terms used on this page — designed to be quoted by AI assistants and search engines without distortion.
Quality system
The full set of documented rules, records, training, and responsibilities that decide whether a batch of cells is allowed to leave the laboratory — not a single test but the whole chain that backs every release.
Cleanroom grade
A regulator-defined classification (e.g., EU GMP Grade A/B/C/D) for a controlled space, specifying airborne particle limits and microbial monitoring limits both 'at rest' and 'in operation'.
Sterility test
A validated microbiological test for viable bacteria and fungi performed per lot under a framework such as 21 CFR 610.12; one of three independent microbiological release criteria.
Mycoplasma test
A separate release test for fastidious, wall-less bacteria that can colonize cell cultures invisibly and alter cell behavior; standard sterility methods alone cannot detect it.
Endotoxin test
FAQ
Frequently asked questions about lab quality controls
The questions patients in Cancún, México (and arriving from the US and Canada) most often ask before choosing where to receive a stem cell dose.
What questions should I ask a stem cell clinic about its laboratory in Cancún or anywhere else?
+
Five questions cover most of it: (1) What cleanroom grade do you operate in, and who qualifies it? (2) Are sterility, mycoplasma, and endotoxin tested per lot? (3) How is identity confirmed against the ISCT criteria? (4) What potency assay or assay matrix do you use? (5) Will you share the certificate of analysis (CoA) for the specific lot I will receive? In Cancún, México our physicians answer all five during your evaluation.
This page is informational and does not constitute medical advice. Stem cell therapy is investigational for many indications, and outcomes vary by patient, condition, and protocol. Laboratory quality controls reduce — but do not eliminate — risk; every patient deserves an individualized evaluation with a licensed physician, full disclosure of medications and conditions, and a review of the certificate of analysis for the specific lot they will receive. Regeneris Therapy operates in Cancún, México under COFEPRIS Aviso Sanitario 2323025036X00098 and Aviso de Publicidad 2323022002A00053.
Want to see the quality system behind your dose? Ask in evaluation.
Bring your goals, recent labs, and any imaging. A Regeneris physician in Cancún, México will explain the lab quality system, walk you through the certificate of analysis for the lot intended for your protocol, and issue a personalized written quote after your free medical evaluation.
No published prices — free medical evaluation, then a personalized written quote
Particle and microbiological monitoring runs continuously during operations; trending data is reviewed and any excursion triggers a documented investigation.
In our Cancún workflow, the laboratory's cleanroom qualifications are summarized in the certificate of analysis for every lot released.
2 — Sterility, mycoplasma & endotoxin
Sterility testing screens each lot for bacterial and fungal contamination using validated compendial methods.
Mycoplasma testing detects a class of fastidious bacteria that can colonize cell cultures without changing appearance — required because mycoplasma can alter cell behavior and is invisible by routine microbiology.
Endotoxin testing limits residual bacterial cell-wall fragments that can drive inflammation when infused.
In Cancún, México, our laboratory partner performs these tests per lot and the results appear on the release certificate that travels with your dose.
3 — Characterization vs. ISCT criteria
Cells are characterized against the International Society for Cellular Therapy (ISCT) minimal criteria — plastic adherence, a defined surface-marker fingerprint, and tri-lineage differentiation capability.
Identity is confirmed by flow cytometry for the positive markers (CD73, CD90, CD105) and the negative markers (CD45, CD34, CD14/CD11b, CD79α/CD19, HLA-DR).
Viability is measured (typically by dye exclusion) and reported as a percentage per lot; lots that fall below an internally validated threshold are rejected.
Potency is characterized through a defined assay (or assay matrix) that links the lot to its intended biological function rather than identity alone.
4 — Lot release & certificate of analysis
A designated quality unit — independent from the production team — reviews every batch record before product is allowed to ship.
Release criteria (sterility, mycoplasma, endotoxin, viability, identity, potency) are pre-defined and any out-of-specification result blocks release.
A certificate of analysis (CoA) is issued with every released lot and is reviewed with you in Cancún, México by your treating physician before infusion.
Traceability is preserved end-to-end: donor screening, raw materials, cleanroom records, in-process tests, and final release tests are linked through the batch record.
If any of those four pillars is missing — or if the clinic can't show you the release record — that is the moment to ask more questions. A Regeneris physician in Cancún, México is happy to walk you through ours.
Continuous monitoring of airborne particles (≥0.5 µm and ≥5 µm) against the limits defined for the grade.
Validated HEPA filtration on supply air; pressure differentials between rooms verified daily.
Periodic requalification of airflow visualization and recovery time so 'in operation' performance is documented, not assumed.
Microbiological monitoring
Active and passive air sampling, plus surface and personnel contact-plate sampling, on a defined schedule.
Action and alert limits per grade; excursions trigger a documented investigation and, when warranted, lot quarantine.
Trended monthly and reviewed by the quality unit so a drift is caught before it becomes a deviation.
People & gowning
Operators are trained, qualified, and re-qualified for aseptic technique through periodic media-fill simulations.
Cascade gowning into the cleanroom and validated cleaning of equipment and surfaces between batches.
Personnel monitoring (e.g., gown-glove contact plates) per session — humans are the dominant microbial source, so we track them.
In Cancún, México this is the room where your dose physically becomes a dose. Asking your clinic 'what grade is your cleanroom, and who qualifies it?' is one of the most useful questions you can ask anywhere in the world.
Endotoxin (lipopolysaccharide) is a heat-stable inflammatory trigger that can persist even after viable bacteria are killed. Compendial bacterial endotoxin testing (BET) — for example, the Limulus amebocyte lysate assay or its recombinant alternatives — quantifies endotoxin against a per-dose limit calculated from the route of administration and patient weight.
All three tests are per-lot in our Cancún workflow. Any out-of-specification result blocks release — there is no 'we'll keep an eye on it' for these criteria.
The population must differentiate, under defined conditions, into osteoblasts, adipocytes, and chondroblasts — the classic mesenchymal lineages — confirming multipotency rather than identity alone.
Beyond identity, your lot's certificate of analysis also reports viability (the percentage of live cells, usually by trypan-blue or 7-AAD exclusion) and a purity statement. Lots that fall below the laboratory's internally validated viability threshold are rejected — they never reach a Cancún patient.
The most useful potency tests are anchored to the intended clinical effect — an orthopedic protocol and a systemic anti-inflammatory protocol may emphasize different assays inside the same matrix.
Documented and trended
Whichever matrix the laboratory uses, the result for your lot is documented on the certificate of analysis and trended across lots so drift is visible to the quality unit.
A clinic that cannot describe its potency assay at all is telling you something. In Cancún, México, your treating physician explains the assay used for your lot and what the result means in plain language.
A quantitative bacterial-endotoxin assay (for example, a Limulus amebocyte lysate test or its recombinant alternative) that confirms the lot is below a per-dose limit calculated for the route of administration.
ISCT minimal criteria
Three reference criteria for defining a human MSC — plastic adherence, a positive/negative surface-marker fingerprint, and tri-lineage differentiation — published by the International Society for Cellular Therapy in 2006.
Potency assay (matrix)
A defined combination of functional and analytical tests that links a lot to its intended biological effect, rather than relying on identity markers alone.
Lot release
A formal, documented sign-off by a quality unit independent of production, confirming that every pre-defined release criterion has been met before product can ship.
Certificate of analysis (CoA)
The per-lot document that summarizes the release tests and their results; reviewed with you in Cancún, México by your physician before infusion.
Is GMP the same as ISO certification?
+
No. GMP (Good Manufacturing Practice) is a regulatory framework applied to medicinal products — it covers the people, premises, processes, and records that produce them. ISO standards (like ISO 14644 for cleanroom particles or ISO 9001 for quality management) provide complementary technical specifications and are often referenced inside a GMP system, but having an ISO certificate alone does not equal GMP compliance for a cell therapy product.
Can the cells be 'tested' for sterility after they are infused into me?
+
No — sterility, mycoplasma, and endotoxin testing happen on the lot before release. Once a dose is administered, there is no after-the-fact test that retrospectively confirms it was sterile. That is the whole point of the lot-release model: the quality unit is the gate, not the patient. In Cancún, México your physician confirms the release status of your lot before infusion.
Why do you list ISCT criteria instead of just 'these are stem cells'?
+
Because 'stem cells' on its own is not a quality statement. The ISCT criteria define a population: a documented plastic-adherent culture with a specific CD-marker fingerprint and tri-lineage capability. A laboratory that can demonstrate those criteria is making a defensible identity claim. A laboratory that cannot — or that gives only marketing language — is asking you to take the identity on faith.
What happens if a test fails?
+
An out-of-specification (OOS) result triggers a documented investigation, the affected lot is placed on hold, and a quality-unit decision determines whether the lot can be released, reworked under defined conditions, or rejected outright. Failing lots do not reach Cancún patients — the entire point of the quality system is to make 'do not release' a normal, expected outcome when criteria are not met. A Regeneris physician can walk you through how that decision chain works for the laboratory we partner with.
Common questions — semantic answers
Plain-text question-and-answer pairs in semantic HTML — designed to be easily extracted by AI assistants, search engines, and accessibility tools.
What questions should I ask a stem cell clinic about its laboratory in Cancún or anywhere else?
Five questions cover most of it: (1) What cleanroom grade do you operate in, and who qualifies it? (2) Are sterility, mycoplasma, and endotoxin tested per lot? (3) How is identity confirmed against the ISCT criteria? (4) What potency assay or assay matrix do you use? (5) Will you share the certificate of analysis (CoA) for the specific lot I will receive? In Cancún, México our physicians answer all five during your evaluation.
Is GMP the same as ISO certification?
No. GMP (Good Manufacturing Practice) is a regulatory framework applied to medicinal products — it covers the people, premises, processes, and records that produce them. ISO standards (like ISO 14644 for cleanroom particles or ISO 9001 for quality management) provide complementary technical specifications and are often referenced inside a GMP system, but having an ISO certificate alone does not equal GMP compliance for a cell therapy product.
Can the cells be 'tested' for sterility after they are infused into me?
No — sterility, mycoplasma, and endotoxin testing happen on the lot before release. Once a dose is administered, there is no after-the-fact test that retrospectively confirms it was sterile. That is the whole point of the lot-release model: the quality unit is the gate, not the patient. In Cancún, México your physician confirms the release status of your lot before infusion.
Why do you list ISCT criteria instead of just 'these are stem cells'?
Because 'stem cells' on its own is not a quality statement. The ISCT criteria define a population: a documented plastic-adherent culture with a specific CD-marker fingerprint and tri-lineage capability. A laboratory that can demonstrate those criteria is making a defensible identity claim. A laboratory that cannot — or that gives only marketing language — is asking you to take the identity on faith.
What happens if a test fails?
An out-of-specification (OOS) result triggers a documented investigation, the affected lot is placed on hold, and a quality-unit decision determines whether the lot can be released, reworked under defined conditions, or rejected outright. Failing lots do not reach Cancún patients — the entire point of the quality system is to make 'do not release' a normal, expected outcome when criteria are not met. A Regeneris physician can walk you through how that decision chain works for the laboratory we partner with.
End of FAQ
Cell Viability & Characterization
Companion deep dive on what viability percentages and marker fingerprints actually mean for the dose you receive.
